Evaluation of Hormone Replacement Therapy in Breast Cancer Patients

Abstract

The aim of the study is to evaluate hormone replacement therapy for breast cancer patients. The goals are to analyses the evaluation of progesterone and estrogen level in a breast cancer in patient, to evaluate and management of hormone replacement therapy breast cancer and to evaluate the role of HER 2 receptor in breast cancer. For a six-month period, a prospective observational study was conducted among the patients in the oncology department at the Erode Cancer Center in Thindal. The investigation was not open to patients who were younger than 20 or who refused to participate in the trial. Reports on prescription patterns, co-morbidity, and individual demography were made available. The current study was conducted in the 100-bed inpatient oncology department.  All female and male patients with breast cancer who were at least 20 years old and willing to provide consent were included in the study. The study excluded individuals who are not willing to participating in the study, severally ill patients, Patient who are below 20 years of age, Pediatrics patients. To obtain the necessary patient data, a correctly designed data collection form was utilized to gather information from patient interviews and the medical file. Clinical pharmacy services will be expanded in patient care through the use of a validated questionnaire and concluded that 70% of patients with metastatic breast cancer have hormone receptor-positive, HER2-positive illness, our study concluded that the main reason for the metastatic breast cancer is that HER-2-positive hormone levels was found to be increased.